Introduction: Impaired diabetic wound healing is an important issue in diabetic complications. The present study aims to evaluate the protective eff ect on glycemic control against impaired diabetic wound healing using a diabetic rat model. We investigated the wound healing process and eff ect on the impaired wound repair by glycemic control in the Spontaneously Diabetic Torii (SDT) fatty rat, which is a new animal model of obese type 2 diabetes and may be a good model for study impaired wound healing. Material and methods: Male SDT fatty rats at 15 weeks of age were administered orally with sodium glucose co-transporter (SGLT) 2 inhibitor for 3 weeks. Wounds were induced at 2 weeks after SGLT 2 inhibitor treatment, and the wound areas were periodically examined in morphological and histological analyses. Results:
INTRODUCTION
Diabetes mellitus is one of the most common chronic diseases all over the world, and continues to increase in numbers: in 2011, 366 million people worldwide suff ered from diabetes, it is estimated to increase to 552 million in 2030 (1) . Th e growing population of diabetic patients has resulted in a rapid increase in the number of patients who have diabetic complications; microangiopathy, such as nephropathy, retinopathy, and neuropathy, and macroangiopathy, such as ischemic heart disease, stroke, and peripheral vascular disease which leads to diabetic foot ulcers and the amputation (2) (3) (4) . In addition to adverse eff ects on the quality of life in the patients, the increasing number of patients contributes importantly to rising medical costs (5, 6) .
Approximately 4-10% of diabetic patients suff er from diabetic foot ulcers and the patients often require surgery, potentially causing chronic wounds, and the impaired wound repair is connected to increases of morbidity and mortality (7) . Also, the formation of wounds is connected to neuropathy with loss of sensitivity, decreased blood fl ow, and impaired ability to high infection (8) . Th e pathogenesis of a diabetic wound are complicated, and the wound repair has a dynamic process involving many factors, and cell types, such as soluble mediators, blood cells, fi broblasts, endothelial cells, and extracellular matrix (9, 10).
New animal models of impaired wound repair with diabetes mellitus are required to elucidate the pathogenesis of diabetic wound and develop the new therapies and the new drugs. Th e Spontaneously Diabetic Torii (SDT) fatty rat, established by introducing the fa allele of the Zucker fatty rat into the SDT genome, is a new model of obese type 2 Diabetes. Th e SDT fatty rat showed overt obesity, and hyperglycemia and dys-ORIGINAL PAPER lipidemia were observed at a young age. With the early incidence of diabetes, the diabetic complications were seen at younger ages as compared with those in other type 2 diabetic models (4, 11, 12) . In the study of diabetic peripheral neuropathy, the SDT fatty rat showed a delay of motor nerve conduction velocity and a decrease of the number of sural nerve fi bers (13) . In this study, we investigated the characteristics of impaired wound healing in the SDT fatty rats and the eff ects of glycemic control on the impaired wound healing.
MATERIALS AND METHODS

Animals and treatment
Male SDT fatty rats (CLEA Japan, Tokyo, Japan) at 15 weeks of age were used for the study. Age-matched male Sprague-Dawley (SD) rats (CLEA Japan, Tokyo, Japan) were used as control animals. All animal procedures and protocol complied with the guidelines for animal experimentation set by the Ethics Committee for Animal Use at Tokyo University of Agriculture or Niigata University.
Th e rats were maintained at 23 ± 3°C on a 12h/12h light-dark cycle with ad libitum access to a standard diet (CRF-1; Oriental Yeast, Tokyo, Japan) and water. Th e rats were administered orally with either vehicle (0.5% methyl cellulose, control group) or sodium glucose co-transporter inhibitor canaglifl ozin 10 mg/kg (SGLT2-I group) suspended in a vehicle once daily for 3 weeks. samples were collected from the tail vein to determine the blood chemical parameters, such as glucose, triglyceride (TG), total cholesterol (TC), and insulin levels. Moreover, glycated hemoglobin (HbA1c) level was measured on Day 7. Th ese biochemical parameters were measured using commercial kits as in our previous study (14) .
Measurement of biological parameters
Morphological and histological analyses
Wounds were induced at 2 weeks after the canaglifl ozin-treatment. Th e skin on the back of anesthetized and took the analgesic rats were shaven and disinfected. Two circular wounds (20 mm in diameter) were made on the skin of left and right sides on the back (Day 0) (9). Th e wound area was determined by the average value of areas on both sides and was measured on Day 5 and Day 11. Th e relative wound size was expressed according to the following formula; % wound area = wound area on Day 5 or 11/wound area on Day 0.
Necropsy was performed at 18 weeks of age. Th e skin was fi xed at 10% neutral buff ered formalin. After resection, tissues were paraffi n-embedded using standard techniques and thin-sectioned (3 to 5 µm). Sections were stained with hematoxylin and eosin (HE).
Statistical analysis Data analysis was expressed as the mean ± standard deviation. Statistical analyses of diff erences between mean values were performed using an F-test, followed by a Student's t-test or Aspin-Welch's t-test. Diff erences were defi ned as signifi cant at p < 0.05.
RESULTS
In biological analysis, body weight, plasma glucose, TG, TC, and insulin levels, and HbA1c level were measured (Figure 1 ). Plasma glucose levels in the SGLT2-I group signifi cantly decreased at Days 0 and 7, as compared with those in the control group ( Figure 1B) . Moreover, HbA1c level in the SGLT2-I group is lower than that in the control group (control, 11.2 ± 0.4% vs. SGLT2-I, 8.6 ± 0.8%) ( Figure 1F ). Plasma TG levels in the SGLT2-I group decreased at Day 0, as compared with that in the control group ( Figure 1C) . Body weight and plasma TC and insulin levels in the SGLT2-I group were comparable to those in the control group ( Figures 1A, 1D, and 1E) .
Changes in % wound area (wound-size) were shown in Figure 2 . Th e representative photograph in each group was shown in Figure 3 . Th e wound-size in SDT fatty rats signifi cantly increased as compared with those in SD rats at Days 5 and 11 (Day 5; SDT fatty rat 95.7 ± 10.0% vs. SD rat 82.5 ± 6.7%, Day 11; SDT fatty rat 55.5 ± 16.6% vs. SD rat 32.1 ± 3.1%). Th e wound-size in SDT fatty rats by SGLT2-I treatment signifi cantly decreased, as compared with that in the control group at Day 5 (control group 95.7 ± 10.0% vs. SGLT2-I group 79.4 ± 5.5%). Moreover, the wound-size of the SGLT2-I group showed a tendency to decrease at Day 11 (control group 55.5 ± 16.6% vs. SGLT2-I group 37.5 ± 10.0%).
On histopathology (Figure 4) , prominent fi brosis, slight infl ammatory cell infi ltration, and neovascularization were observed in normal SD rats. However, severe infi ltration of infl ammatory cell and hemorrhage and many bacterial masses in the crust on skin tissue were seen and slight fi brosis that were noted in SDT fatty rats. In addition, cystic formation in subcutaneous tissue was diff usely observed in SDT fatty rats. Th ese fi ndings in SDT fatty rats were ameliorated and/or slightly observed in the SGLT2-I treated group.
DISCUSSION
In this study, we investigated the characteristics of skin repair in male SDT fatty rats, using the SGLT 2 inhibitor canaglifl ozin. Canaglifl ozin is a novel anti-diabetic drug and the drug show a glucose lowering eff ect by inhibiting glucose re-absorption in the proximal renal tubules (15, 16) . Th e SDT fatty is a new diabetic model (17) , and the plasma glucose, TG, and TC levels increased as compared with those levels in SD rat, as shown in previous studies (4, 11, 18) .
Th e normal wound healing mechanism is composed of several steps, homeostasis, infl ammation, granulation, tissue formation, and tissue remodeling. Moreover, the delayed healing is caused by defective regulation of the complex molecular and biological factors involved in proper healing (19, 20, 21) . Th ese factors reportedly include impaired keratinocyte, fi broblast, macrophage function, aberrant angiogenic response, and growth factor production (8) . It is also reported that impaired wound healing is caused by the presence of advanced glycosylation end (AGE) products or increase of reactive oxygen species (ROS) production (22, 23) . In this study, the SDT fatty rats by canaglifl ozin-treatment sustained a good glycemic control during the experimental period, and the glycemic controlled led to the recovery eff ect on the delayed wound healing in SDT fatty rats. Th is pharmacological eff ect is considered to be induced by the decreases of AGE or ROS production by glycemic control.
Th e diabetic complications, including microangiopathy and macroangiopathy are caused by the uncontrolled diabetes mellitus for long-term (24) . On the other hand, impairment of wound healing is caused by the shortterm controlled. In this study, also, the impaired wound healing in SDT fatty rats is improved by glycemic control for short-term, 2-3 weeks. In histological analyses in the skin, prominent fi brosis, slight infl ammatory cell infi ltration, and neovascularization were observed in normal SD rats; however, a delay of crust formation and regeneration of the epithelium and many bacterial masses in the crust on skin tissue were noted in SDT fatty rats. Th ese changes in SDT fatty rats showed a delayed wound healing in diabetes. In addition, these fi ndings in SDT fatty rats were ameliorated and progressed of wound healing by the glycemic control with the SGLT2-I treatment.
It is reported that tight glycemic control is a key factor in wound healing in other experimental diabetic models (25) . In the Goto-Kakizaki rat, a non-obese type 2 diabetic model, a glycemic control with metformin-treatment improved the peri-implant wound healing (26) . Also, in the streptozotocin-induced diabetic rats, the glycemic control showed a therapeutic potential in treatment of diabetic wounds (27).
CONCLUSION
Glycemic control is eff ective for treatment in diabetic wounds and thought that the SDT fatty rat will be useful to investigate the pathophysiological changes in impaired diabetic wound healing.
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